Phase II results published in medical journal and Redwood Pharma to present poster at medical meeting
The results of Redwood Pharma's Phase II study of RP101 have now been published in the medical journal Advances in Therapy and will also be presented as a scientific poster presentation at the forthcoming annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).In 2020, Redwood Pharma completed a Phase II clinical trial in Europe of RP101, the company's drug candidate for the treatment of chronic dry eye in post-menopausal women. The results have now been published in Advances in Therapy, an international scientific journal in clinical medicine. See link: